hip and knee joint disease
Conditions
Interventions
A:TXA 1.5g i.v. q12h, before surgery
B:NS 100ml i.v. q12h, before surgery
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: All patients who were scheduled to have hip surgery for hip fracture (femoral neck fractures, intertrochanteric fractures, subtrochanteric fractures, pelvic fractures, acetabular fractures) were considered eligible for included in the trial.
Exclusion criteria
Exclusion criteria: Allergy to tranexamic acid; preoperative hepatic or renal dysfunction; preoperative use of anticoagular medication seven days prior to surgery; history of fibrinolytic disorder or blood dyscrasia; cerebrovascular accident, myocardial infarction, New York heart association class III or IV heart failure, atrial fibrillation, history of deep vein thrombosis or pulmonary embolus, preoperative INR >1.4, aPTT >1.4 x normal, platelets <140000/mm3.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| total blood loss;hidden blood loss;intraoperative blood loss;fibrinolysis index (D-Dimer, FDP) ;nflammatory index (PCT, CRP, ESR, IL-6, IL-8, IL-10, TNF-a);coagulation indicator (PT, APTT, INR) ;TEG;antifactor Xa activity ;Hb drop;transfusion; | — |
Secondary
| Measure | Time frame |
|---|---|
| range of motion;incidence of thrombosis (DVT PE);incision related complications ;readmission rate;ecchymosis;length of stay;hospitalization expenses;VAS score;death; | — |
Countries
China
Contacts
Public ContactWei Huang
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed